(312) 275-5850 9-5pm CST
0 CART $0.00
Your shopping cart is empty.
CIA Medical Google Customer Reviews – Central Infusion Alliance
CIA Medical BBB Accredited A+ Business – Central Infusion Alliance
CIA Medical Digicert EV Secure – Central Infusion Alliance
Menu

Baxter 2B0088 - 5% Dextrose Injection Solution, USP, VIAFLEX, 50 mL 96/case

Baxter # 2B0088 - 5% Dextrose Injection Solution, USP, VIAFLEX, 50 mL 96/case
Part Number Baxter 2B0088
SKU Number CIA7006683
Sell Unit CASE
Ships Within Backorder
List Price $608.08
Enter a valid quantity
Product Description

Baxter 2B0088 - 5% Dextrose Injection Solution, USP, VIAFLEX, 50 mL 96/case

Baxter 2B0088 - 5% Dextrose Injection Solution, USP, VIAFLEX, 50 mL 96/case

Dextrose injection is a sterile solution that provides hydration and carbohydrates (calories from sugar). It is used when treating low blood sugar and water loss without electrolytes. Water loss without electrolytes can happen in episodes of fever, high blood calcium, hyperthyroidism or diabetes. Dextrose is also effective when treating high blood potassium, diabetic ketoacidosis and as parenteral nutrition. Dextrose solution can also be used as a diluent when preparing injectable medications in an IV bag. The diluent provides a good amount of liquid to dilute a small amount of medicine. This facilitates the process of carrying medicine into the bloodstream through the IV, allowing the caregiver to administer medicine in a slow manner so it goes safely into the patient's body.

5% Dextrose Injection Dosage and Administration

  • Dextrose injection is indicated as a source of water calories and intended for intravenous use.
  • Peripheral administration of 5% dextrose is usually acceptable, however, consider central vein when administering more than 5% dextrose or with an osmolarity of at least 900 mOsm/L or when there is peripheral vein irritation, phlebitis, and/or associated pain.
  • Dextrose Injection should not be administered simultaneously with blood products through the same IV set due the risk of causing pseudo agglutination or hemolysis.
  • In order to prevent air embolism, opt for a non-vented infusion set or close the vent on a vented set, avoid multiple connection, do no connect flexible containers in series, fully evacuate residual gas in the container to increase flow rates, and if administration is controlled by a pumping device, turn off pump before the container runs dry.
  • Examine the diluted dextrose solution to search for particulate matter prior to infusion. The solution should be clear and there should be no precipitates. Do not administer unless solution is clear, and container is undamaged. Using a final filter is recommended during administration of parenteral solutions when possible.

5% Dextrose Injection Recommended Dosage

Rate and volume of dextrose concentration depends on the patients age, weight, clinical and metabolic conditions and concomitant therapy. Electrolyte supplementation may be needed according to the clinical needs of the patient. The administration rate should be monitored, especially for premature infants with low birth weight, during the first few days of therapy, by the patients tolerance to dextrose.

Dextrose Solution Warnings and Precautions

The use of dextrose infusions in patients with impaired glucose tolerance may worsen hyperglycemia. Administration of dextrose at a rate exceeding the patients utilization rate may lead to hyperglycemia, coma and death. Hyperglycemia is associated with an increase in serum osmolality, resulting in osmotic diuresis, dehydration and electrolyte losses. Patients with underlying CNS disease and renal impairment who receive dextrose infusions, may be at greater risk of developing hyperosmolar hyperglycemic state. Monitor blood glucose levels and treat hyperglycemia to maintain levels within normal limits while administering Dextrose Injection. Insulin may be administered or adjusted to maintain optimal blood glucose levels during Dextrose Injection administration.

Hypersensitivity and infusion reactions, including anaphylaxis, have been reported with Dextrose Injection. Stop infusion immediately and treat patient accordingly if signs or symptoms of a hypersensitivity reaction develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated.

Peripheral administration of 5% Dextrose Injection is generally acceptable, however, consider central vein when administering more than 5% dextrose or with an osmolarity of = at least 900 mOsm/L or when there is peripheral vein irritation, phlebitis, and/or associated. The infusion of hypertonic solutions into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis. The primary complication of peripheral access is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible, if thrombophlebitis develops.

Depending on the tonicity of the solution, the volume and rate of infusion, and depending on a patients underlying clinical condition and capability to metabolize glucose, intravenous administration of glucose can cause electrolyte disturbances, most importantly hypo- or hyperosmotic hyponatremia. Monitor serum sodium to minimize the risk of hyponatremia. The risk for hyponatremia is increased in pediatric patients, elderly patients, postoperative patients, those with psychogenic polydipsia, and in patients treated with medications that increase the risk of hyponatremia (such as diuretics, certain antiepileptic and psychotropic medications). Close clinical monitoring may be warranted. Acute hyponatremia can lead to acute hyponatremic encephalopathy characterized by headache, nausea, seizures, lethargy and vomiting. Patients with brain edema are at particular risk of severe, irreversible and life-threatening brain injury. Patients at increased risk for developing complications of hyponatremia, such as hyponatremic encephalopathy include pediatric patients; women, in particular, premenopausal women; patients with hypoxemia; and in patients with underlying central nervous system disease. Avoid Dextrose Injection in patients with or at risk for hyponatremia. If use cannot be avoided, monitor serum sodium concentrations.

Depending on the volume and rate of infusion, the patients underlying clinical condition and capability to metabolize dextrose, intravenous administration of Dextrose Injection can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, (including hypoosmotic hyponatremia), overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations in the administered solution. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations in the solution. Avoid Dextrose Injection in patients with or at risk for fluid and/or solute overloading. If use cannot be avoided, monitor fluid balance, blood electrolyte levels, concentration of glucose, acid-base balance, correct fluid and electrolyte imbalances during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation and acid-base balance as needed and especially during prolonged use. Additional monitoring is recommended for patients with water and electrolyte disturbances that could be aggravated by increased glucose, insulin administration and/or free water load. Patients at increased risk for developing hyponatremic encephalopathy include pediatric patients; elderly patients, women, in particular premenopausal women; patients with hypoxemia; and patients with underlying

Baxter 2B0088

VIAFLEX Plastic Container Feature

The VIAFLEX Plus plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). VIAFLEX Plus on the container indicates the presence of a drug additive in a drug vehicle. The VIAFLEX Plus plastic container system utilizes the same container as the VIAFLEX plastic container system. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2- ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.

  • Manufacturer: Baxter 2B0088
  • Application: Caloric Agent
  • Container Type: Flexible Bag
  • Dosage Form: IV Solution
  • Generic Drug Name: Dextrose / Water
  • Strength: 5%
  • Type: Intravenous
  • Volume: 50mL
  • VIAFLEX Plastic Container
  • MADE IN USA
Related Products